Compare Devon Energy Corp (DVN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Inovio Pharmaceuticals Inc — how do they compare? Devon Energy Corp trades at $48.28 (market cap $53.81B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Devon Energy Corp is far larger — about 479.6× Inovio Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DVN | INO | |
|---|---|---|
Market Cap | $53.81B | $112.19M |
Volume | 11,556,740 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $52.07 | $2.65 |
52-Week Low | $31.74 | $0.66 |
Typical Hold Time | 136 Days | 43 Days |
Enterprise Value | $64.55B | $83.51M |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.26, up 0.79% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 10.63 and net margin of 16.67%, supported by recent earnings beats. Analyst consensus is strongly bullish with a $62.53 price target, representing 30% upside potential. Recent news highlights activist investor pressure for strategic alternatives including potential sale, while BP shows interest in acquiring Eagle Ford assets.
DVN presents compelling value with attractive valuation metrics and solid profitability. Key opportunities include potential asset sales and Permian Basin strength, while risks involve oil price volatility and execution of strategic initiatives. The stock's current valuation discount to analyst targets suggests significant upside if operational improvements materialize.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
